October 2021 Newsletter

House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship   The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar.   The bill calls for a “temporary increase in Medicare Part B payments for certain biosimilars,” […]

Read More


September 2021

ASBM Welcomes Ralph McKibbin, MD as Chairman   In a Full Member Call September 9th, ASBM introduced gastroenterologist Ralph McKibbin, MD, FACP, FACG, AGAF as the organization’s incoming chairman. Dr. McKibbin began his three year term on September 1st, succeeding outgoing chair Madelaine Feldman, MD, FACR. Dr. McKibbin is the fourth chairman since ASBM was […]

Read More


July-August 2021 Newsletter

Madelaine Feldman Completes Term as ASBM Chair   On August 31st, ASBM Chair Madelaine Feldman, MD, FACR completed her term as ASBM Chair.   ASBM Executive Director Michael Reilly praised Dr. Feldman’s leadership:   Dr. Feldman led ASBM during a difficult time, keeping ASBM engaged on important biosimilar policy issues during the COVID-19 pandemic. As […]

Read More


June 2021 Newsletter

Minnesota Budget Passes Without Biosimilar Provisions    On June 29th, Minnesota Governor Tim Walz signed his state’s HHS Omnibus  budget for 2022-2023. The legislature had considered but ultimately rejected language aimed at boosting uptake of biosimilars – provisions which many patient groups believed might inadvertently increase out-of-pocket costs.   Since April, ASBM and other organizations including […]

Read More


May 2021 Newsletter

ASBM Launches Online Biosimilars Course for Pharmacists   ASBM, in conjunction with the Long Island University College of Pharmacy (LIU-Pharmacy), is now offering a comprehensive continuing education course on biosimilars entitled “Biosimilars: What Pharmacists Need to Know”. The course is accredited by the American Council on Pharmaceutical Education (ACPE), meaning course credit is available to […]

Read More


April 2021 Newsletter

Oklahoma Becomes Final State to Permit Biosimilar Substitution    On April 22nd, Oklahoma Governor Kevin Stitt signed SB 4, making Oklahoma the 50th and final state to enact a law permitting biosimilar substitution.   SB 4, like similar legislation in other states, permits interchangeable biosimilars to be substituted at the pharmacy level once approved by […]

Read More


March 2021 Newsletter

ASBM Leads Three Panel Discussions at Festival of Biologics USA 2021   From March 29th-31st ASBM representatives led three panel discussions at the World Biosimilar Congress USA 2021, part of the annual Festival of Biologics USA. Typically held in San Diego, CA, the event was conducted virtually this year due the COVID-19 pandemic.   On March 29th, […]

Read More


February 2020

Controversial Biosimilar Switching Policy in Canada in 2021    As of February, two Canadian provinces, British Columbia and Alberta, have implemented or partially implemented forced biosimilar non-medical switching policies. The controversial policies drew strong objections from many in the GI patient and physician community.   In a 2017 survey, more than 2/3 of Canadian physicians surveyed said […]

Read More


January 2020

ASBM’s Andrew Spiegel Interviewed on Susan G. Komen Podcast On January 28, the Susan G. Komen Foundation released an episode of their podcast “Real Pink” entitled  “The Evolution of Biosimilars as a Cancer Treatment” featuring Andrew Spiegel. Mr. Spiegel is Executive Director of the Global Colon Cancer Association and a founding member of ASBM.    In the […]

Read More


December 2020

ASBM Paper is GaBI Journal’s Most-Read Biosimilars Article of 2020 According to the editors of the Journal of the Generics and Biosimilar Initiative (GaBI Journal), the most-viewed biosimilars article of 2020 was the whitepaper “Policy recommendations for a sustainable biosimilars market: lessons from Europe”, co-authored by ASBM’s Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. […]

Read More